Abstract: Modafinil is selectively delivered to the brain, minimizing delivery to the blood, of a person in need thereof by administering to the person a therapeutically-effective dosage of modafinil, wherein the dosage is less than 1 mg, formulated in a lipid microemulsion (LME) and selectively delivered to the upper third of the nasal cavity. The method may be implemented with an intranasal pharmaceutical delivery device loaded with a modafinil composition and adapted to deliver the dosage to the upper third of the nasal cavity.
Type:
Grant
Filed:
February 6, 2009
Date of Patent:
August 2, 2011
Assignees:
SRI International, HealthPartners Research Foundation
Inventors:
Mary Ann Katherine Greco, William Howard Frey, II, Jacqueline DeRose, Rachel Beth Matthews, Leah Ranae Bresin Hanson
Abstract: This invention relates to novel macrocyclic lactams intermediates useful for the preparation of diazonamide analogs. This invention also relates to a novel electrochemical oxidative cyclization for the preparation of such macrocyclic lactams, and their further elucidation to provide diazonamide analogs.
Type:
Grant
Filed:
October 3, 2010
Date of Patent:
July 19, 2011
Assignees:
Board of Regents, The University of Texas System, Joyant Pharmaceuticals, Inc.
Inventors:
Gunnar Hanson, Charles Caldwell, Patrick G. Harran, Susan Harran, Qi Wei, Ming Zhou
Abstract: Anti-inflammatory compositions include medicaments comprising predetermined amounts of a phytyl substituted chromanol and a prostaglandin E2 inhibitor, wherein: said medicament is in unit dosage form suitable for pharmaceutical administration; said phytyl substituted chromanol is a gamma-tocopherol, delta-tocopherol, gamma-tocotrienol or delta-tocotrienol; said PGE2 inhibitor is a non-steroidal anti-inflammatory drug or an omega-3 fatty acid, such as docosahexaenoic acid and eicosapentaenoic acid.
Type:
Grant
Filed:
June 22, 2005
Date of Patent:
June 21, 2011
Assignee:
Children's Hospital & Research Center at Oakland
Abstract: Diazonamide A analogs, and the salts, esters and conjugates thereof, having improved aqueous solubility are provided. Also provided are pharmaceutical compositions, and methods for preparing and using such compounds and compositions for the treatment of proliferative diseases.
Abstract: A composition for oral radionuclide chelation therapy comprises a DTPA chelate selected from Zn-DTPA and Ca-DTPA and a permeation enhancer that preferentially increases jejunal uptake of the DTPA chelate. The composition has a DTPA chelate bioavailability of at least 10% of the chelate when orally administered to a mammal.
Type:
Grant
Filed:
February 14, 2007
Date of Patent:
March 29, 2011
Assignee:
SRI International
Inventors:
Gita Natarajan Shankar, Helen Jaber Parish
Abstract: Metal binding polycarboxylated porphyrins, their precursors, or cofactors in the porphyrin biosynthetic pathway, are administered to individuals determined to be subject to or predisposed to a polycarboxylated porphyrin-binding metal toxicity to increase the level of the metal-binding polycarboxylated porphyrin in the individual.
Type:
Grant
Filed:
January 29, 2005
Date of Patent:
March 15, 2011
Assignee:
Children's Hospital & Research Center at Oakland
Abstract: A lanthanide chelate is linked to a noble metal substrate at a proximity wherein the substrate enhances a fluorescent emission of the lanthanide by at least 20-fold when the chelate is illuminated at an excitation wavelength that induces a transition in the lanthanide that results in the fluorescent emission.
Abstract: Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of The compoundic mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.
Type:
Grant
Filed:
July 24, 2009
Date of Patent:
February 8, 2011
Assignee:
Board of Regents, The University of Texas System
Inventors:
Patrick G. Harran, Xiaodong Wang, Jef K. De Brabander, Lin Li, Ranny Mathew Thomas, Hidetaka Suzuki
Abstract: Disclosed are methods and compositions for determining whether a person carries an allele associated with increased risk for coronary atherosclerosis by determining whether the person has had RA-CHR9 allele, such as by determining whether the person has an RA-CHR9 allele-associated single nucleotide polymorphism (SNP).
Type:
Grant
Filed:
May 21, 2007
Date of Patent:
February 8, 2011
Assignee:
Board of Regents, The University of Texas System
Abstract: Small fiber neuropathy is treated by topically administering to a subject in need thereof topically active quinoline compounds or pharmaceutically acceptable salts thereof under conditions effective to treat neuropathy in the subject. Glial cell-derived neurotrophic factor (GDNF) receptors are modulated with the subject active quinoline compounds, which may be formulated in topical lotions.
Abstract: This invention relates to novel macrocyclic lactams intermediates useful for the preparation of diazonamide analogs. This invention also relates to a novel electrochemical oxidative cyclization for the preparation of such macrocyclic lactams, and their further elucidation to provide diazonamide analogs.
Type:
Grant
Filed:
June 6, 2008
Date of Patent:
December 14, 2010
Assignees:
Board of Regents, The University of Texas System, Joyant Pharmaceuticals, Inc.
Inventors:
Gunnar Hanson, Charles Caldwell, Patrick G. Harran, Susan Harran, Qi Wei, Ming Zhou
Abstract: A polynucleotide is barcoded using a method whereby an isolated, individual polynucleotide is immobilized on a solid phase and stretched, targets are labeled using target-specific hybridization probes, and an individual label of an unamplified probe at each of the labeled targets is optically detected. The order of the labels is determined to form a barcode representation of the polynucleotide wherein the targets and their relative positions are represented.
Type:
Grant
Filed:
October 28, 2004
Date of Patent:
November 9, 2010
Assignees:
Board of Trustees of the University of Illinois, Regents of the University of California
Inventors:
Paul R. Selvin, Matthew Gordon, Pui-Yan Kwok, Ming Xiao, Ting-Fung Chan
Abstract: Tissue preservation media comprising a polyoxyethylene/polyoxypropylene copolymer are used to preserve tissues and organs for storage and transplantation. In particular embodiments, the polyoxyethylene/polyoxypropylene copolymer is Pluronic F68 or FLOCOR (CRL-5861; purified poloxamer 188), and the medium is Steinhardt medium, polyoxyethylene/polyoxypropylene copolymer-supplemented Optisol GS or polyoxyethylene/polyoxypropylene copolymer-supplemented ViaSpan.
Abstract: Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of The compoundic mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.
Type:
Grant
Filed:
July 24, 2009
Date of Patent:
October 19, 2010
Assignee:
Board of Regents, The University of Texas System
Inventors:
Patrick G. Harran, Xiaodong Wang, Jef K. De Brabander, Lin Li, Ranny Mathew Thomas, Hidetaka Suzuki
Abstract: The invention provides small molecule mimics of the Smac peptide that are dimer- or dimer-like compounds having two amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders.
Type:
Grant
Filed:
March 21, 2007
Date of Patent:
October 5, 2010
Assignee:
Joyant Pharmaceuticals, Inc.
Inventors:
Gunnar J. Hanson, David Thomas, Nizal Chandrakumar, Susan Harran
Abstract: Hypoxic tissue is preserved by prophylactically administering Stromal Derived Factor 1 Alpha (SDF-1?) before hypoxia induces cell death in the tissue.
Type:
Grant
Filed:
January 20, 2006
Date of Patent:
August 17, 2010
Assignee:
Board of Regents, The University of Texas System
Abstract: Improved methods of genetic haplotyping and DNA sequencing and mapping, including methods for making amplified ssDNA, methods for allele determination, and a DNA barcoding strategy based on direct imaging of individual DNA molecules and localization of multiple sequence motifs or polymorphic sites on a single DNA molecule.
Type:
Grant
Filed:
December 14, 2007
Date of Patent:
August 10, 2010
Assignees:
The Board of Trustees of the University of Illinois, Regents of the University of California
Inventors:
Ming Xiao, Pui-Yan Kwok, Paul Selvin, Mathew Gordon
Abstract: Inhibitors of Nogo Receptor (NgR)-p75 binding are used to reduce NgR-p75 binding mediated axon growth inhibition. Mixtures of NgR and p75 are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to p75 and promoting axon regeneration.
Type:
Grant
Filed:
August 2, 2002
Date of Patent:
June 29, 2010
Assignee:
Children's Medical Center Corporation
Inventors:
Zhigang He, Kevin C. Wang, Jieun A. Kim